Tomorrow is the start of #ESCCongress 2024! Check out the sessions featuring presentations and contributions from DCRI faculty and fellows, and stay tuned to our page for more session and conference updates. #clinicaltrials #clinicalresearch #cardiology
Duke Clinical Research Institute
Research Services
Durham, North Carolina 18,597 followers
Developing & sharing knowledge that improves health around the world through innovative clinical research.
About us
As part of the Duke University School of Medicine, the Duke Clinical Research Institute (DCRI) is known globally for conducting groundbreaking multinational trials, managing major national patient registries, and performing landmark research. As an academic clinical research organization, we combine the faculty expertise of practicing physicians with the full-service operational capabilities of a major CRO. We design and implement innovative clinical trials that advance the understanding of health and disease and inform efforts to improve the quality of care. Our experience stretches from phase I to phase IV and beyond, encompassing post-approval analyses and health economics. The breadth of our work in numerous therapeutic areas is matched by the depth of our knowledge, which we disseminate through high-impact publications and global meetings. Since 1996, DCRI's faculty and staff have disseminated over 17,500 peer-reviewed publications and have been cited in over 760,500 scientific articles.
- Website
-
https://dcri.org
External link for Duke Clinical Research Institute
- Industry
- Research Services
- Company size
- 1,001-5,000 employees
- Headquarters
- Durham, North Carolina
- Type
- Educational
- Founded
- 1969
Locations
-
Primary
300 W Morgan St
Durham, North Carolina 27701, US
Employees at Duke Clinical Research Institute
Updates
-
Earlier this year, TAILORED-AF found AI-guided cardiac ablation improved long-term outcomes for persistent atrial fibrillation – the first large, randomized, and multicenter trial to do so. DCRI’s Jonathan Piccini, MD, MHS shares why he believes the technology used in this trial is special, and what it may mean for future research: https://lnkd.in/euZmnBNx #clinicaltrials #clinicalresearch #cardiology #AI
-
-
Can counseling interventions that promote walking in patients with symptomatic peripheral artery disease reduce the risk of major adverse cardiac events? DCRI’s Jennifer Rymer provides her analysis of a recent clinical trial exploring this question in a new commentary for JAMA Surgery: https://lnkd.in/eAC43mTi #clinicaltrials #clinicalresearch #hearthealth #cardiovascular
-
DCRI's Rob Mentz recently joined the CardioNerds podcast to discuss iron deficiency and the impact it has on heart failure with Daniel Ambinder, Amit Goyal, Jenna Skowronski, and Dr. Shazli Khan. Listen to the full episode to where they they cover the diagnostic criteria of iron deficiency in heart failure, review clinical trials, cover areas for future research, and more: https://lnkd.in/ebGj-K9B #clinicaltrials #clinicalresearch #heartfailure #irondeficiency
388. Ironing out the Data: Iron Deficiency in Heart Failure with Dr. Robert Mentz
https://www.cardionerds.com
-
What major changes can we expect to see in cardiovascular disease prevention over the next century? According to DCRI’s Adrian Hernandez, genetics-related technologies such as gene editing and data from wearable devices are poised to play a key role in identifying, treating, and preventing CV disease. Learn more about the innovations he and other experts in the field expect to see in the next 100 years: https://lnkd.in/eXVpHKnZ #clinicalresearch #genetics #cardiology #heartdisease
What might the next century hold for cardiovascular disease prevention and care?
heart.org
-
Despite evidence showing the benefits of SGLT2 inhibitors for patients with diabetes, heart failure, and kidney disease, new data found the uptake of these inhibitors for eligible patients in the U.S. remains extremely low – a problem that has “unfortunately [led] to a lot of preventable deaths and hospitalizations that could have been avoided if we had timely initiation,” says DCRI’s Stephen Greene. Learn more about why he and other experts says increasing SGLT2 usage should be an “all-hands-on deck” situation: https://lnkd.in/eydQThew #clinicaltrials #clinicalresearch #heartfailure #diabetes
Only Small Minority of Eligible Patients Prescribed SGLT2 Inhibitors
tctmd.com
-
The AMETHYST randomized clinical trial, which features DCRI’s Rob Mentz as a contributing author, sought to gauge how a combination of verinurad and allopurinol impacted exercise capacity and symptoms in patients with HFpEF and elevated serum uric acid levels. Read the full study results at JAMA Cardiology: https://lnkd.in/eH_hQj6a #clinicaltrials #randomizedtrials #heartfailure #hearthealth
Verinurad Plus Allopurinol for HFpEF
jamanetwork.com
-
While heart disease is more common among older demographics, experts like DCRI’s Nishant Shah agree that it’s never too early to start practicing healthy heart habits. See why he and others say starting a regular exercise routine when younger can help prevent heart disease later on in life, along with tips on how to start your own exercise regimen: https://lnkd.in/ehYDK6q8 #hearthealth #heartdisease #exercise
The 1 Heart-Health Habit You Should Start When You’re Young
time.com
-
Recent data suggest that glucagon-like peptide-1 receptor agonists improve kidney outcomes for people with type 2 diabetes. DCRI authors Daniel Edmonston, Keith Marsolo, Schuyler Jones and Neha Pagidipati sought direct comparisons of the kidney and cardiovascular effectiveness of GLP-1 RA with sodium-glucose cotransporter 2 inhibitors, a first-line therapy for this population, in a new study: https://lnkd.in/dZ4zEyHr #clinicaltrials #clinicalresearch #cardiovascular #kidney
Kidney and Cardiovascular Effectiveness of SGLT2 Inhibitors vs GLP-1 Receptor Agonists in Type 2 Diabetes
sciencedirect.com
-
Beta blockers are a type of medication commonly used to treat heart conditions, cardiovascular disease, and situational anxiety. But how exactly do they work, and what should you know about taking them? DCRI’s Nishant Shah joins other experts to discuss the effects, use cases and potential side-effect of the drugs in a new article for Cosmopolitan: https://lnkd.in/eNacmjiD #hearthealth #cardiovasculardisease #anxiety
Every Single Thing to Know About Beta Blockers for Anxiety
cosmopolitan.com